Alterity Therapeutics adds new director Ann Cunningham

Alterity Therapeutics Limited, a development-stage enterprise based in Melbourne, submitted a Form 6-K as a foreign private issuer.

Rhea-AI Filing Summary

Alterity Therapeutics Limited, a development-stage enterprise based in Melbourne, submitted a Form 6-K as a foreign private issuer. The filing is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.

Through an attached Appendix 3X, Alterity reports the appointment of Ann Cunningham as a director effective 17 April 2026. The notice states that she currently has no relevant interests in Alterity securities as a registered holder.

Key Figures

Director appointment date: 17 April 2026

1 metrics

Director appointment date 17 April 2026 Ann Cunningham appointed as director of Alterity Therapeutics

Key Terms

Form 6-K, foreign private issuer, Appendix 3X, listing rule 3.19A.1, +1 more

5 terms

Form 6-K regulatory

"SECURITIES AND EXCHANGE COMMISSION FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Appendix 3X regulatory

"Exhibit 99.1 Appendix 3X Initial Director’s Interest Notice"

listing rule 3.19A.1 regulatory

"information under listing rule 3.19A.1 and as agent for the director"

section 205G of the Corporations Act regulatory

"for the purposes of section 205G of the Corporations Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Alterity Therapeutics (ATHE) report in this Form 6-K?

Alterity Therapeutics uses this Form 6-K to furnish an Appendix 3X Initial Director’s Interest Notice. It primarily reports the appointment of director Ann Cunningham and confirms she currently holds no Alterity securities as a registered holder at the time of appointment.

Who is the new director disclosed by Alterity Therapeutics (ATHE)?

The filing identifies Ann Cunningham as a new director of Alterity Therapeutics. Her appointment date is listed as 17 April 2026. The accompanying Appendix 3X indicates she has no relevant interests in Alterity securities as a registered holder on appointment.

When did Ann Cunningham join the board of Alterity Therapeutics (ATHE)?

Ann Cunningham’s appointment as a director is dated 17 April 2026. This date is disclosed in the Appendix 3X Initial Director’s Interest Notice attached to the Form 6-K, which Alterity lodged in compliance with ASX and Corporations Act disclosure requirements.

Does Ann Cunningham hold any Alterity Therapeutics (ATHE) shares on appointment?

According to the Appendix 3X, Ann Cunningham has no relevant interests in Alterity securities as a registered holder. The sections for number and class of securities, nature of interest, and registered holder details are all marked N/A in the director’s interest notice.

How is this Alterity Therapeutics (ATHE) Form 6-K used with other SEC registrations?

The Form 6-K states it is incorporated by reference into Alterity’s existing Form S-8 and Form F-3 registration statements. This means the information about the new director and related disclosure becomes part of those effective U.S. securities registration documents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 06:02 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Initial Director's Interest Notice - Cunningham

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: April 21, 2026

2

Exhibit 99.1

Appendix 3X
Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Alterity Therapeutics Limited

ABN 37 080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ann Cunningham
Date of appointment	17 April 2026

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil.

+ See chapter 19 for defined terms.

11/3/2002

Appendix 3X  Page 1

Appendix 3X
Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.         N/A       Number & class of Securities             Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.

Appendix 3X  Page 2 11/3/2002

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 23.1 KB